×
About 17,948,885 results

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
https://www.nejm.org/doi/full/10.1056/NEJMoa2110345?query=featured_coronavirus
The New England Journal of Medicine; Thomas SJ, Moreira ED et. al.

Sep 15th, 2021 - BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein. BNT162b2 is highly efficacious against coronavirus disease 2019 (Covid-19) and is currently approved, conditionally approved, or authorized for emergency use worldwide. At the time ...

American Heart Association Hypertension Guideline Toolkit
http://aha-clinical-review.ascendeventmedia.com/books/aha-high-blood-pressure-toolkit/
American Heart Association

AHA High Blood Pressure Toolkit

Obinutuzumab Provides Two-Year Benefits for Lupus Nephritis
https://www.hcplive.com/view/obinutuzumab-two-year-benefits-lupus-nephritis

Nov 4th, 2020 - After promising 18-month outcomes in patients with proliferative lupus nephritis, obinutuzumab showed sustained benefits through 2 years of treatment for patients burdened with the rheumatic disease.

Machine Learning Could Benefit Rheumatoid Arthritis Treatment with Sarilumab
https://www.hcplive.com/view/machine-learning-benefit-rheumatoid-arthritis-treatment-sarilumab

Nov 3rd, 2020 - As interleukin receptor (IL) inhibitors, the monoclonal antibody drug class has come to revolutionize fields of inflammatory disease care, though the utility and resourcing of such promising agents is yet to be fully refined. Namely, clinicians can stand to benefit from more biomarkers, more indications by which monoclonal antibodies are most impactful.

ESMO Virtual Congress 2020 Science Weekend Program
https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/session/calendar

Sep 19th, 2020 - ESMO Virtual Congress 2020 Science Weekend Online Program

ESMO Guidelines: COVID-19 Adapted Recommendations Slide Sets
https://www.esmo.org/guidelines/covid-19-adapted-recommendations-slide-sets

Sep 19th, 2020 - The core content of each COVID-19 adapted recommendation is presented in a user-friendly format ready for you to use in your own presentations, both to illustrate your own cases and research, as well as for educational purposes. Please note that while you may use slides individually from the sets for personal use, it is strictly forbidden to alter or hide any of the content, the ESMO logo, the ...

ESMO Virtual Congress 2020: Abstracts
https://www.esmo.org/meetings/esmo-virtual-congress-2020/abstracts

Sep 19th, 2020 - Abstract submission categories Basic science Biliary tract cancer, incl. cholangiocarcinoma Biomarkers (agnostic) Breast cancer, early stage Breast cancer, locally advanced Breast cancer, metastatic CNS tumours Colorectal cancer Developmental therapeutics Endocrine tumours Genitourinary tumours, prostate Genitourinary tumours, non-prostate Gynaecological cancers Haematological mal...

ESMO Virtual Congress 2020: Exhibition
https://www.esmo.org/meetings/esmo-virtual-congress-2020/exhibition

Sep 19th, 2020 - With the new virtual platform, the aim is twofold: on one side to offer an experience which will be able to meet the needs of the many eager to find a fruitful learning opportunity; on the other, we are committed to still offer an engaging networking space, all delivered via state-of-the-art technology. Further information in this regard will be published progressively on this webpage soon.

ESMO: COVID-19 and Cancer
https://www.esmo.org/covid-19-and-cancer?hit=ehp

Sep 19th, 2020 - Updates, guides, webinar series, recommendations, more.

ESMO Webinar Series: Managing Patients in the COVID-19 Era
https://www.esmo.org/meetings/esmo-webinar-series/managing-patients-in-the-covid-19-era

Sep 19th, 2020 - This Webinar series has been organised with the aim to share the ESMO adapted recommendations for cancer patient management during the COVID-19 pandemic. These recommendations should be used as guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of cancer patients.

ESMO Virtual Congress 2020: Program
https://www.esmo.org/meetings/esmo-virtual-congress-2020/programme

Sep 19th, 2020 - The ESMO Virtual Congress 2020 Programme is now online! The ESMO Virtual Congress 2020 will be the global stage for the exchange and debate of translational cancer science of excellence, first announcements of practice-changing data, and multidisciplinary must-have conversations set to spur transformative therapies against cancer.

ESMO Virtual Congress 2020: ESMO Colloquia
https://www.esmo.org/meetings/esmo-virtual-congress-2020/esmo-colloquia

Sep 19th, 2020 - The ESMO Colloquia are innovative sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community. The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and education programme of the Congress.

ESMO Virtual Congress 2020: FAQs
https://www.esmo.org/content/download/313751/6378320/ESMO-Virtual-Congress-2020-FAQs.pdf

Sep 19th, 2020 - ESMO Virtual Congress 2020: Frequently Asked Questions

ESMO
https://www.esmo.org/

Sep 19th, 2020 - EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY The leading professional organisation for medical oncology

ESMO COVID-19 Full Coverage
https://www.esmo.org/covid-19-and-cancer/covid-19-full-coverage

Sep 19th, 2020 - The COVID-19 pandemic has brought new challenges to clinical practice and research in oncology. ESMO is reporting on the current situation by news and KOLs experiences, and has gathered useful resources to keep medical oncologists updated.

ESMO Virtual Congress 2020: Meeting
https://www.esmo.org/meetings/esmo-virtual-congress-2020

Sep 18th, 2020 - Bringing innovation to cancer patients. The ESMO Virtual Congress 2020 will present promising new developments aimed at improving cancer patient care. In response to the needs of the moment, the scientific programme will include a dedicated COVID-19 and cancer research track. Take part in Europe's most prestigious platform for oncology stakeholders.

ESMO: COVID-19 and Cancer Care in the ESMO Journals
https://www.esmo.org/covid-19-and-cancer/covid-19-and-cancer-care-in-the-esmo-journals

Sep 18th, 2020 - In this page you can find the articles related to COVID-19 disease in the context of cancer care management as published in the ESMO flagship journal, the Annals of Oncology and the ESMO Open.

ESMO Guideline for Cancer Patient Management During the COVID-19 Pandemic
https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic?hit=ehp

Sep 18th, 2020 - These recommendations should be used as guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of cancer patients. The situation is evolving, and pragmatic actions may be required to deal with the challenges of treating patients, while ensuring their rights, safety and wellbeing.

ACR 2020 Permissions and Reprints
https://www.rheumatology.org/Annual-Meeting/Abstracts/Permissions-and-Reprints

Sep 7th, 2020 - ACR Convergence, the ACR's annual meeting, is a private event. Programs presented at the meeting are for the education of attendees and purchasers of recorded presentations as authorized by the American College of Rheumatology. The information and materials displayed and presented during this meeting are the property of the ACR and the presenter and cannot be photographed, copied, photocopied, ...

ACR 2020 Frequently Asked Questions
https://www.rheumatology.org/Annual-Meeting/Resources

Sep 7th, 2020 - Please refer to the Frequently Asked Questions (FAQs) below for more information on the all-virtual ACR Convergence 2020. We will share more details as they become available in the coming weeks and months.

WFH Guidelines for the Management of Hemophilia, 3rd edition
https://onlinelibrary.wiley.com/doi/10.1111/hae.14046
Haemophilia

Aug 3rd, 2020 - This new edition of the World Federation of Hemophilia (WFH) guidelines for the management of hemophilia comes at an exciting time in the evolution of the diagnosis and treatment of this condition. Since the publication of the second edition in 2012, tremendous advances have been made in several aspects of the management of hemophilia. These include genetic assessment as well as therapy with ma...

Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2768602
JAMA Internal Medicine;

Jul 15th, 2020 - Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection began in December 2019 in Wuhan, China, more than 6 million people have developed coronavirus disease 2019 (COVID-19), and more than 350 000 have died.1 Critical illness from COVID-19 in China, Italy, and other countries has strained intensive care unit (ICU) resources and produced a wide spectrum of sh...

Researchers gain insight into factors influencing immunotherapy response in kidney cancer
https://www.healio.com/news/hematology-oncology/20200710/researchers-gain-insight-into-factors-influencing-immunotherapy-response-in-kidney-cancer

Jul 10th, 2020 - Tumor mutational burden is considered a hallmark indicator of a tumor’s potential for response to immunotherapy. PD-1 checkpoint inhibitors such as pembrolizumab (Keytruda, Merck) and nivolumab (Opdivo, Bristol-Myers Squibb) have been shown to be more effective in treating tumors with high mutational burden. However, despite having only a moderate number of mutations, advanced clear cell ren...

Lisocabtagene maraleucel CAR T shows durable response in large B-cell NHL
https://www.healio.com/news/hematology-oncology/20200709/lisocabtagene-maraleucel-car-t-shows-durable-response-in-large-bcell-nhl

Jul 9th, 2020 - In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.

Retreatment with CAR-T therapy shows clinical efficacy in lymphoma
https://www.healio.com/news/hematology-oncology/20200708/retreatment-with-cart-therapy-shows-clinical-efficacy-in-lymphoma

Jul 8th, 2020 - In a small sample, retreatment of patients with large B-cell lymphoma showed good response, notably in patients who had complete response on initial treatment, according to a poster presented at ASCO 2020 Virtual Scientific Program.

Expert Perspective on ASCO20 Quality Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200237/full/

Jul 7th, 2020 - This essential study (Abstract 2003) highlights that health policy impacts cancer survival. It showed that age-adjusted mortality from cancer is worse in states that have not expanded access to Medicaid under the Affordable Care Act. There were 758 fewer cancer deaths in expansion states in 2017, and Hispanic populations had the greatest decrease in mortality under Medicaid expansion. This stud...

Avelumab ‘opens up the door’ for immunotherapy in trophoblastic disease
https://www.healio.com/news/hematology-oncology/20200707/avelumab-opens-up-the-door-for-immunotherapy-in-trophoblastic-disease

Jul 7th, 2020 - A study presented during the ASCO2020 Virtual Scientific Program showed ‘impressive’ use of immunotherapy for gestational trophoblastic disease, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Olaparib shows 1-year survival benefit in recurrent ovarian cancer, BRCA mutations
https://www.healio.com/news/hematology-oncology/20200707/olaparib-shows-1year-survival-benefit-in-recurrent-ovarian-cancer-brca-mutations

Jul 7th, 2020 - Overall survival results from SOLO-2 showed patients with recurrent ovarian cancer and germline BRCA mutations added a year of life when treated with olaparib only, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Patient survival greatly impacted by selection for ovarian cancer relapse surgery
https://www.healio.com/news/hematology-oncology/20200707/patient-survival-greatly-impacted-by-selection-for-ovarian-cancer-relapse-surgery

Jul 7th, 2020 - Studies presented during the ASCO2020 Virtual Scientific Program showed the benefit of validated selection tools in pursuing surgical measures for ovarian cancer relapse, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.

Expert Perspectives on the ASCO20 Plenary Session
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200236/full/

Jul 6th, 2020 - The JAVELIN Bladder 100 study (LBA1) investigated the efficacy of maintenance avelumab following platinum-based chemotherapy compared to best supportive care for patients with metastatic urothelial cancer. In the trial, avelumab improved median overall survival by 21.4 months compared to 14.3 months with best supportive care. These data are practice changing, and the degree of benefit to this a...

Dual target CAR T-cell therapy effective, durable, less toxic in lymphoma
https://www.healio.com/news/hematology-oncology/20200706/dual-target-car-tcell-therapy-effective-durable-less-toxic-in-lymphoma

Jul 6th, 2020 - A novel CAR T-cell therapy targeting both CD19 and CD22 showed less toxicities than current CAR T-cell therapies while producing complete response with accepted regimens, according to a study presented at ASCO2020 Virtual Scientific Program.

Immunotherapy and Beyond: Treatment Options and Potential Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200227/full/

Jul 3rd, 2020 - Head and neck cancers account for approximately 4% of all cancers in the United States1 and are the eighth most common cancer affecting men in the United States.2 The diagnosis of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) carries a poor prognosis, with an overall survival (OS) of approximately 1 year.

Expert Perspective on ASCO20 Gynecologic Oncology Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200233/full/

Jul 3rd, 2020 - DESKTOP III (Abstract 6000) is a prospective, multicenter, randomized phase III study of > 400 patients with platinum-sensitive, recurrent ovarian cancer that demonstrated a clinically meaningful 7.7 month improvement in median overall survival with secondary cytoreductive surgery (53.7 months) compared with no surgery (46 months).

Expert Perspective on ASCO20 Genitourinary Cancers Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200232/full/

Jul 3rd, 2020 - The phase III HERO trial (Abstract 5602) investigated the results of relugolix, an orally bioavailable GnRH receptor antagonist, for patients with advanced prostate cancer. Treatment with relugolix resulted in superiority over leuprolide in achieving sustained testosterone suppression. Additionally, treatment was associated with faster testosterone recovery and decreased major adverse cardiovas...

Expert Perspective on ASCO20 Gastrointestinal Cancers Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200231/full/

Jul 2nd, 2020 - Donafenib, a deuterated derivative of sorafenib, was tested against sorafenib in the frontline setting in hepatitis B– associated hepatocellular carcinoma (HCC) in a large, multi-institutional study in China (Abstract 4506).

Expert Perspective on ASCO20 Immunotherapy Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200234/full/

Jul 2nd, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) has emerged to be a game-changer as shown by this first pivotal phase II trial of CAR T-cell therapy in multiple myeloma (MM). Ide-cel is a first-in-class BCMA-directed CAR T-cell therapy, with 4-1BB costimulatory domain and CD3Z T-cell activation domain.

COVID-19 in Immunocompromised Hosts: What We Know So Far
https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa863/5864040
Clinical Infectious Diseases; Monica Fung MD, MPH et. al.

Jun 27th, 2020 - The coronavirus disease 2019 (COVID-19) pandemic caused by SARS coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features and outcomes of COVID-19 among immunosuppressed patients, who are at presumed risk for more severe disease but who may also have decreased detrimental inflammatory responses, are no...

New Kidney Cancer Research From the ASCO20 Virtual Scientific Program Demonstrates an Exciting, Evolving Field
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200216/full/

Jun 25th, 2020 - There used to be a paucity of options for managing advanced renal cell cancer (RCC) with a high toxicity profile including traditional chemotherapy, interferon, and interleukins. With the advent of tyrosine kinase inhibitors (TKIs) in 2007 followed by immunotherapy over the past few years, a paradigm shift emerged in managing this increasingly prevalent disease with its associated high morbidit...

Top Lung Cancer Research Presented at the ASCO20 Virtual Scientific Program Has Implications for Clinical Practice
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200223/full/

Jun 25th, 2020 - Although the ASCO Annual Meeting felt much different this year given the virtual format, the quality of research presented at the meeting was undiminished, particularly in the field of lung cancer. ASCO Daily News Expert Panel member Jared Weiss, MD, of the University of North Carolina School of Medicine, reviewed the most influential lung cancer research presented during the ASCO20 Virtual Sci...

Breast Cancer Research at ASCO20 Virtual Scientific Program Highlights New Avenues and Better Outcomes
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200222/full/

Jun 25th, 2020 - The ASCO20 Virtual Scientific Program featured a variety of important and innovative breast cancer research. The following are some of the studies with potential to significantly impact clinical practice and patient outcomes, as selected by ASCO Daily News Expert Panel member Arielle Heeke, MD, of the Levine Cancer Institute.

Clinical Implications of First-Line Pembro for MSI-High mCRC
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200220/full/

Jun 24th, 2020 - Long-awaited results from the randomized, phase III KEYNOTE-177 trial provide strong support for using single-agent pembrolizumab instead of a chemotherapy-based regimen in patients newly diagnosed with metastatic colorectal cancer (mCRC) featuring high-level microsatellite instability (MSI-H) or deficient mismatch repair (dMMR; Abstract LBA4).

ECOG-ACRIN Trial Reassures Clinicians, Patients That Locoregional Therapy Is Not Beneficial for Stage IV Metastatic Breast Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200218/full/

Jun 24th, 2020 - For patients with stage IV metastatic breast cancer and an intact primary tumor (ITP), the early initiation of locoregional treatment (LRT) was not associated with longer survival or improvements in health-related quality of life (HRQoL) compared with systemic therapy alone, according to a phase III clinical trial (Abstract LBA2). These findings appear to add to a robust evidence base that sugg...

Switch Maintenance With Avelumab Changes Treatment Paradigm for Advanced Urothelial Carcinoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200217/full/

Jun 24th, 2020 - A switch maintenance therapy approach using the immune checkpoint inhibitor avelumab in patients with advanced urothelial carcinoma (UC) who had not progressed after induction platinum-based chemotherapy offered significantly improved survival outcomes, according to results of the JAVELIN Bladder 100 trial (Abstract LBA1). The study, which was the first UC study ever presented during an ASCO An...

Will DFS Benefit Translate Into Survival Benefit in ADAURA?
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200221/full/

Jun 24th, 2020 - The report on ADAURA during the ASCO20 Virtual Scientific Program Plenary Session surprised many, first because the initial data readout for the phase III trial was not planned until 2022 and second because of the strength of the disclosed data (Abstract LBA5). Early unblinding of the results revealed an 83% reduction in the risk of disease recurrence or death with use of adjuvant osimertinib c...

KRd, VRd Equivalency in Multiple Myeloma ‘Reassuring’ to Hematologists
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200219/full/

Jun 24th, 2020 - Awaited results of the ENDURANCE trial showed equivalency between a regimen of carfilzomib plus lenalidomide and dexamethasone (KRd) and bortezomib, lenalidomide, and dexamethasone (VRd) as an initial therapy for patients with standard- or intermediate-risk multiple myeloma (Abstract LBA3). KRd failed to improve progression-free survival compared with VRd, according to data presented by Shaji K...

Trastuzumab Achieves Slight Reduction in Recurrence for Women With HER2-Positive DCIS
https://ascopost.com/news/june-2020/trastuzumab-achieves-slight-reduction-in-recurrence-for-women-with-her2-positive-dcis/

Jun 8th, 2020 - The addition of trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) in the NRG Oncology clinical trial NSABP B-43. The trial did find a modest (19%) reduction in the rate of recurrence among women who received trastuzumab, but this difference was not stati...

RET Kinase Inhibitor for Patients With Solid Tumors and RET Genetic Fusions
https://ascopost.com/news/june-2020/ret-kinase-inhibitor-for-patients-with-solid-tumors-and-ret-genetic-fusions/

Jun 5th, 2020 - The RET inhibitor pralsetinib showed activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the phase I/II ARROW trial, presented by Vivek Subbiah, MD, and colleagues during the ASCO20 Virtual Scientific Program (Abstract 109).

Results From an Oncology Hospital-at-Home Evaluation
https://ascopost.com/news/june-2020/results-from-an-oncology-hospital-at-home-evaluation/

Jun 5th, 2020 - Researchers at Huntsman Cancer Institute (HCI) at the University of Utah presented the first outcomes evaluation of an adult oncology hospital-at-home program during the ASCO20 Virtual Scientific Program (Abstract 7000). The study evaluated patients participating in HCI's Huntsman at Home program. The data demonstrated strong evidence for the benefits of this care model, showing improved patien...

Cediranib/Olaparib vs Standard-of-Care Chemotherapy for Platinum-Sensitive Ovarian Cancer
https://ascopost.com/news/june-2020/cediranibolaparib-vs-standard-of-care-chemotherapy-for-platinum-sensitive-ovarian-cancer/

Jun 2nd, 2020 - Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival outcomes for women with platinum-sensitive ovarian cancer; however, activity between the treatments was similar in patients. These results were recently presented by Joyce ...

Remote Pre- and Posttest Genetic Counseling for Breast and Ovarian Cancer Risk
https://ascopost.com/news/june-2020/remote-pre-and-post-test-genetic-counseling-for-breast-and-ovarian-cancer-risk/

Jun 2nd, 2020 - Genetic testing for cancer risk can significantly improve the prevention or treatment of hereditary cancers, but studies have shown that people who might have a genetic risk often don't get tested. A collaborative team of researchers have tested a possible solution through a clinical trial aimed at making genetic testing more accessible. The trial, called MAGENTA (Making GENetic Testing Accessi...